Skip to content
The Saltzman family’s Dis-Chem stake surged by $53.5 million, recovering earlier losses and reinforcing their position among South Africa’s richest investors amid renewed market confidence.
Adani Ports is evaluating a push into South Africa as it seeks to expand across African trade routes after turbulence slowed its international momentum.
This comes after a tough period earlier in the year when Seabrooke saw his wealth dip by $6.35 million due to a decline in the company’s stock price.
This fresh setback extends a rough stretch for Ravazzotti, whose fortune had already taken a heavy blow earlier in the year.
Anglo American has won shareholder approval to spin off its platinum arm, Valterra Platinum, effective May 31, 2025, as part of a major restructuring.
In April, Kirsh, through his family office Ki Corporation, teamed up with Public Storage to bid for Abacus Storage King.
Reinet, led by Johann Rupert, posts $7.89 billion in net assets as it shifts away from tobacco and toward diversified, long-term investment growth.
The company warned that its South African PGM operations may no longer be viable if prices don’t recover soon.
A recent dip in FMB Capital’s share price on the Malawi Stock Exchange has shaved $183 million off Hitesh Anadkat’s investment.
This development comes after an inspection in 2022 that revealed lapses in Absa's adherence to critical regulatory requirements.
This follows a $148.7 million contract dispute tied to mRNA technology.
Conservationists have fought against the project from the start, warning it could cause lasting damage to one of South Africa’s most sensitive ecosystems.
Richemont finalizes $609.7 million YNAP divestment to Mytheresa, marking a major shift in luxury e-commerce and boosting Mytheresa’s global market position.
The upgrade is part of Vukile’s ongoing effort to invest with real purpose, shaping spaces that are built around the people who use them every day.
Sibanye-Stillwater narrows 2024 loss to $311 million under Neal Froneman, showing signs of recovery amid weak metal markets and operational restructuring.
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.